Company Overview and News

1
Biotechs Emerge Unscathed And Ready To Go!

2018-05-15 seekingalpha
The blueprint to lower drug prices leaves biotechs unscathed and can be a net positive for the biopharma industry.

2
MRTX / Mirati Therapeutics, Inc. 10-Q (Quarterly Report)

2018-05-07 sec.gov
Document Table of Contents UNITED STATES

 
Small Caps: The Bright Spot In A Challenging Stock Market

2018-05-07 seekingalpha
Risk appetite remains positive with small caps demonstrating resilience throughout the consolidation phase, and model portfolios recording double-digit gains.

 
2 Small Biotechs To Consider

2018-04-27 seekingalpha
To end the trading week, we look at two biotech stocks that appear to have attractive risk/reward profiles at current trading levels.

2
MRTX / Mirati Therapeutics, Inc. 8-K (Current Report)

2018-04-24 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

 
MRTX / Mirati Therapeutics, Inc. DEF 14A

2018-04-20 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION

2
Merck Wins Big Against Rivals in Lung Cancer Study Survival Rates

2018-04-17 247wallst
Lung cancer may have just met a new standard of care. On top of that, it would be considered a new standard as a first line of care in lung cancer and longer overall survival rates. Shares of Merck & Co. Inc. (NYSE: MRK) saw an increase in value while shares rival drug maker Bristol-Myers Squibb Co. (NYSE: BMY) traded lower after lung cancer study results were presented at the American Association for Cancer Research annual meeting.

3
MRTX / Mirati Therapeutics, Inc. FORM 8-K (Current Report)

2018-04-10 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

8
Biotechs Approaching New Waters

2018-03-20 seekingalpha
The biotech sector also continues to benefit from potential M&A, faster drug approvals, strong risk appetite, and improving public sentiment.

 
MRTX / Mirati Therapeutics, Inc. 10-K (Annual Report)

2018-03-08 sec.gov
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

14h - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

14h - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 60468T105